Bottemanne Hugo, Arnould Alice, Najar Amaury, Delaigue Fanny, Serresse Laure, Joly Lucie, Mouchabac Stéphane
Paris Brain Institute - Institut du Cerveau (ICM), UMR 7225/UMRS 1127, Sorbonne University/CNRS/Inserm, Paris, France; Sorbonne University, Department of Philosophy, SND Research Unit, UMR 8011, CNRS, Paris, France; Department of Psychiatry, Pitié-Salpêtrière Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Department of Psychiatry, Pitié-Salpêtrière Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Encephale. 2023 Jun;49(3):304-311. doi: 10.1016/j.encep.2022.08.011. Epub 2023 Apr 22.
Obsessive-Compulsive Disorder (OCD), characterized by the combination of obsession and compulsion, is a clinical and therapeutic challenge. Many patients with OCD do not respond to first-line treatments such as serotonin selective reuptake inhibitors (SSRIs) and exposure and response prevention psychotherapy (ERP). For these resistant patients, some preliminary studies have shown that ketamine, a non-selective glutamatergic NMDA receptors antagonist, could improve the obsessive symptoms. A number of these studies have also suggested that the combination of ketamine with ERP psychotherapy may jointly potentiate the effectiveness of ketamine and ERP. In this paper, we present the existing data on the combined use of ketamine with ERP psychotherapy for OCD. We suggest that modulation of NMDA receptor activity and glutamatergic signaling by ketamine may promote the therapeutic mechanisms involved in ERP such as fear extinction and brain plasticity mechanisms. Finally, we propose a ketamine-augmented ERP psychotherapy (KAP-ERP) protocol in OCD, and we present the limitations associated with its application in clinical practice.
强迫症(OCD)以强迫观念和强迫行为并存为特征,是临床治疗中的一项挑战。许多强迫症患者对一线治疗方法无反应,如5-羟色胺选择性再摄取抑制剂(SSRIs)以及暴露与反应阻止心理治疗(ERP)。对于这些难治性患者,一些初步研究表明,氯胺酮,一种非选择性谷氨酸能NMDA受体拮抗剂,可改善强迫症状。其中多项研究还表明,氯胺酮与ERP心理治疗联合使用可能会共同增强氯胺酮和ERP的疗效。在本文中,我们展示了氯胺酮与ERP心理治疗联合用于强迫症的现有数据。我们认为,氯胺酮对NMDA受体活性和谷氨酸能信号的调节作用可能会促进ERP中涉及的治疗机制,如恐惧消退和脑可塑性机制。最后,我们提出了一种用于强迫症的氯胺酮增强ERP心理治疗(KAP-ERP)方案,并阐述了其在临床实践应用中的局限性。